APA (7th ed.) Citation

Tarantelli, C. (2018). PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy. The American Association for Cancer Research (AACR).

Chicago Style (17th ed.) Citation

Tarantelli, C. PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy. The American Association for Cancer Research (AACR), 2018.

MLA (9th ed.) Citation

Tarantelli, C. PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy. The American Association for Cancer Research (AACR), 2018.

Warning: These citations may not always be 100% accurate.